中国现代医学杂志2024，Vol.34Issue(13)：71-79,9.DOI:10.3969/j.issn.1005-8982.2024.13.010
2型固有淋巴细胞及相关因子在多发性骨髓瘤患者中的研究
Study on type 2 innate lymphocytes and associated moleculars in multiple myeloma patients
摘要
Abstract
Objective To explore the changes in ILC2s and their associated moleculars in the peripheral blood of multiple myeloma(MM)patients.Methods This study included sixty MM patients and forty healthy controls.The proportion of ILC2s cells and the expression of KLRG1 on these cells were analyzed using flow cytometry,while the mRNA levels of GATA-3,ST2,IL-5,IL-13,and IL-7RB were quantified through PCR.Results In newly diagnosed MM patients,there was an increase in the proportion of ILC2s,KLRG1 expression on ILC2s,and the mRNA levels of GATA-3,ST2,IL-5,and IL-13 in PBMC(P＜0.05).Additionally,the proportion of ILC2s cells showed a positive correlation with these associated molecules(r=0.831,0.748,0.737,0.702,and 0.699,P＜0.05).Post-treatment,the remission group exhibited lower levels of ILC2s cells,KLRG1 expression on ILC2s,and mRNA levels of GATA-3,ST2,IL-5,and IL-13 compared to the non-remission group(P＜0.05).Furthermore,these parameters decreased in the remission group post-treatment compared to pre-treatment(P＜0.05).Conversely,in the non-remission group,the proportion of ILC2s cells and associated molecular levels significantly increased post-treatment(P＜0.05).ROC curves demonstrated that pre-treatment levels of KLRG1 expression on ILC2s cells and IL-13 mRNA had significant predictive value for treatment efficacy.Conclusion ILC2s cells contribute to immune dysregulation in MM,promoting tumor growth.These cellular immune disorders may result from alterations in cell-associated effector molecules.关键词
多发性骨髓瘤/二型固有淋巴细胞/免疫紊乱Key words
multiple myeloma/type 2 innate lymphocytes/immune disorder分类
医药卫生引用本文复制引用
钟笛,陈双,骆婷婷,张瑞..2型固有淋巴细胞及相关因子在多发性骨髓瘤患者中的研究[J].中国现代医学杂志,2024,34(13):71-79,9.基金项目
新疆维吾尔自治区自然科学基金青年科学基金(No:2022D1C754) （No:2022D1C754）
